ICER Analyses Increasingly Guide US Price Negotiations, Payers Report
Nearly 65% of respondents reported ICER cost effectiveness reviews are 'likely' or 'extremely likely' to function as a benchmark in price negotiations with manufacturers, according to a recent survey.
You may also be interested in...
Drug makers have sought a larger role for RWE in ICER's review process; proposed update also includes process to re-evaluate cost-effectiveness evidence after one year.
Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.